Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of LY2606368 in Patients With Advanced Cancer.

Trial Profile

A Phase 1 Study of LY2606368 in Patients With Advanced Cancer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prexasertib (Primary)
  • Indications Anal cancer; Cancer; Carcinoma; Head and neck cancer; Non-small cell lung cancer; Skin cancer; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 11 Apr 2018 Results (n=101) of dose expansion phase published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 05 Apr 2017 Results (n=71) of a clinical biomarker analysis of prexasertib in patients with advanced head and neck squamous cancer and squamous cell carcinoma of the anus, presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 19 Apr 2016 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top